Theresa May’s new merger powers would be a hostile takeover by the state October 16, 2018 Back in July 2016, Theresa May launched her campaign for leadership of the Conservative party by promising radical action on foreign takeovers of British businesses. In the wake of Kraft’s takeover of Cadbury and Pfizer’s failed bid for AstraZeneca, May promised to defend workers and local communities from transient shareholders who, she said, were more [...]
AstraZeneca wins approval for major heart attack drug Brilinta in the US September 4, 2015 AstraZeneca has won approval for the sale of a potential blockbuster drug in the US. Brilinta, which thins the blood of former heart attack victims, won approval from the Food and Drug Administration last night, and is expected to be made available in pharmacies from the end of September. Read more: AstraZeneca sells drug [...]
Here’s what we can learn from the 10 biggest deals in pharmaceutical history August 7, 2015 The pharmaceutical world is abuzz about a major deal struck between AbbVie and small biotech company Pharmacyclics last night. The US pharma giant bought Pharmacyclics for a massive $21bn (£13.8bn), after fending off fierce competition from the likes of Johnson & Johnson. Why? To get its hands on the firm's super-successful cancer drug Imbuvrica, whose [...]
Astrazeneca’s revenue better than forecast July 30, 2015 ASTRAZENECA revenue fell by a smaller-than-expected seven per cent in the second quarter, as income from selling rights to medicines offset generic competition to older drugs and a strong dollar. The drugmaker increased its revenue forecast for the year and said it now expected a low single-digit percentage decline, against mid single-digit previously, while core [...]
AstraZeneca sells drug for $215m to Tillotts as it focuses on core products July 9, 2015 AstraZeneca has sold a gastrointestinal drug to Tillotts Pharma, a Swiss based pharmaceutical company, for $215m (£140m) as it slims down to focus on cancer and other core products. The British-Swedish multinational has disposed of all non-US rights for Entocort, a treatment for Crohn’s disease and ulcerative colitis, in the most recent of a string [...]
AstraZeneca chief executive questions UK’s commitment to treating cancer June 3, 2015 AstraZeneca chief executive Pascal Soriot has warned that the UK is lagging behind in cancer care innovation, after the government's drugs approval body rejected a new ovarian cancer drug already used in France and Germany as being too expensive. Read more: Why only Scottish patients are getting the best new drugs on the NHS “How can [...]
General Election: Only Scottish patients are getting the best new drugs on the NHS April 27, 2015 Terminally ill people in Scotland are being given the best new cancer drugs, while those in the rest of the UK are being deprived of them. This apparently unfair difference stems from the way drug provision by NHS England and NHS Scotland is regulated, with Scotland's drug monitoring body making it much easier for [...]
AstraZeneca share price dips despite rise in profits and unchanged outlook April 24, 2015 AstraZeneca had a successful start to the year, but competition means growth will be slow. The figures The Anglo-Swedish drug maker's operating profit went up by 15 per cent to $933m (£620m) during the first three months of the financial year, with revenue also rising by one per cent to $6bn. This is a [...]
General Election 2015: AstraZeneca boss Pascal Soriot distances himself from Conservative supporting Telegraph business leader letter April 2, 2015 The boss of one of the biggest companies in Britain has said he is not backing the Conservatives, despite his name being included in a letter signed by 100 business leaders backing the party's economic policies. Pascal Soriot, chief executive of AstraZeneca, said his name should not have been included in the letter, which was [...]
AstraZeneca and TSB help London reverse declines – London Report March 12, 2015 UK SHARES rose yesterday, led by challenger bank TSB after it received a takeover offer, and by drugs group AstraZeneca on optimism about key trial results. Shares in TSB, which was spun off from Lloyds and listed at 280p per share last year, rose 23 per cent to 326p after it received a takeover bid [...]